Course info
Sections
General
0 activities
801. Gene Therapies: Poster I
0 activities
Enhanced tyrosine kinase inhibitor response on chronic myeloid leukemia cells upon MS4A3 mRNA delivery
1 activities
CD19 antigen From tumor target to safety switch able to improve the safety profile of CAR T cell therapy
1 activities
Long term follow up of the first in human post transcriptional genetic silencing of BCL11A in sickle cell disease in a phase 1 pilot and feasibility trial
1 activities
Robust HbF induction and improvement of anemia and hemolysis with base editing in sickle cell disease Safety and efficacy findings from the ongoing BEACON study
1 activities
Multiplex base editing enhances fetal hemoglobin production in sickle cell disease erythroid cells
1 activities
Targeting the METTL1 m7G axis as a therapeutic strategy in myeloid leukemia
1 activities
MiR 146b restoration in T large granular lymphocyte leukemia Molecular insights for a new therapeutic strategy
1 activities
Prime Editing–Mediated BCL 2 hematopoietic stem cell shielding as a strategy for leukemia therapy
1 activities
8